messag report strong result tuesday impress top line
momentum organ drove earn upsid revenu beat broad base
segment top consensu despit top-lin strength
ep beat howev earn forecast stay larg unchang
combin fx tariff deal dilut expect weigh ep back
half year comp set get tougher continu see share
fairli valu current level walk model chang
beyond
slightli increas adjust ep estim yoy
previous toward high end manag guidanc
rang model call total revenu organ prior
estim cvg forecast solid growth coronari structur heart
cc aortic peripher vascular cc modest
gain cardiac rhythm heart failur cc mitg expect surgic
solut revenu come cc respiratori gastrointestin
renal ad organ sale meanwhil expect rtg growth
boost strength pain therapi cc brain therapi
cc specialti therapi cc partial off-set slight declin
spine cc final increas diabet estim
cc back quarter strong perform
longer term continu see grower top
bottom line respect outlook slightli large-cap med-tech group
averag roughli share trade modest discount peer
price-to-earnings vs basi in-lin ev/ebitda basi
view valuat fair current level maintain neutral rate
sector medic suppli devic
page analyst certif import disclosur
wake covidien merger emerg largest med-tech
compani world boast lead franchis across wide varieti end market
sinc compani work translat unmatch scale competit
advantag includ lead way healthcar landscap shift fee-for-
valu model re-envis mean centuri
devic compani pursu goal deliv econom valu uniqu
combin technolog servic go far beyond tradit purview
med-tech effort mix success date think concept
valu healthcar stay expect fee-for-valu transit play
meantim see execut around compani core financi target
primari driver valu creation front think manag recent
revis lrp set much achiev bar one could even allow compani
deliv upsid street expect time pipelin matur near-term
howev see stock fairli valu given growth trajectori
share current trade ntm ep estim
ntm ebitda repres discount large-cap med-tech group averag
price-to-earnings basi line ev/ebitda view valuat
appropri given project long-term growth profil
top bottom line respect lag behind broader sector averag
better opportun elsewher group view assign
upsid risk rate includ revenu growth exce forecast better-
than-expect execut margin target faster expect shift fee-for-
valu healthcar paradigm benefit compani superior scale play
medtron strength prove disrupt competitor
downsid risk rate includ clinic setback weaker-than-expect adopt
new product caus revenu fall short street estim better-than-expect
share gain competitor failur execut margin expans goal
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
